So many companies are disproportionately affected to varying degrees. Not all up. If you are referring to this news (1), take it with a grain of salt. Look at the % recovery, look at those N's, look at those p values. Gilead is pumping today, but imo this isn't a smoking gun study. The drug needs to be administered to more patients to get more statistical power and draw meaningful conclusions on efficacy.

Then again, wall street doesn't know their N's and p's. Gilead could have put out anything today and the stock would be flying on speculation due to none of the hungover 24 year olds moving millions at goldman sachs actually reading the study, much less interpreting it. Of course, this is just my take. Maybe you are right and this does explain the pump, I guess we will read about it this evening.

1. https://www.gilead.com/news-and-press/press-room/press-relea...

> and the remdesivir drug trial seems to have been a success,

it's what now? I haven't seen any data, including the report today, that it made a significant impact.